Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GST-HG131 in Healthy Subjects
NCT04499443Phase 1Unknown
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GST-HG131 in hepatitis B (HBV) (6 arms), sponsored by Fujian Cosunter Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration at Day 1, Area Under Curve at Day 1 and 2 more. Status: unknown.
02
Drugs
GST-HG131
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04499443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499443.